glp-1 in europe We've just launched a new EuropeActive position paper on medication and sustainable health outcomes. "GLP-1 Medication: Quick Fix or Long-Lasting Solution?" looks at how GLP-1 therapies are reshaping obesity treatment and Health authorities in Europe have

Curr Pharm Des 13(7):663669 Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH (2003) Glucagon-like peptide-1 decreases endogenous amyloid- peptide (A) levels and protects hippocampal neurons from death induced by A and iron

Lets talk about it. What makes the story of GLP-1s particularly interesting is that it started nearly 20 years ago with a twice-daily injection called Byetta, which offered modest A1C reduction and less than 10% weight loss

Think of them as tiny text messages your body actually wants to receive (unlike those spam calls about your cars extended warranty)

When you remove effective therapy for a chronic disease, the biology of that disease has room to reassert itself

By molecule class, the market is divided into semaglutide, tirzepatide, and other molecules